Literature DB >> 26937619

Progress Toward Measles Elimination - Nepal, 2007-2014.

Sudhir Khanal, Tika Ram Sedai, Ganga Ram Choudary, Jagat Narain Giri, Rajendra Bohara, Rajendra Pant, Mukunda Gautam, Umid M Sharapov, James L Goodson, James Alexander, Alya Dabbagh, Peter Strebel, Robert T Perry, Sunil Bah, Nihal Abeysinghe, Arun Thapa.   

Abstract

In 2013, the 66th session of the Regional Committee of the World Health Organization (WHO) South-East Asia Region (SEAR) established a goal to eliminate measles and to control rubella and congenital rubella syndrome (CRS) in SEAR by 2020. Current recommended measles elimination strategies in the region include 1) achieving and maintaining ≥95% coverage with 2 doses of measles-containing vaccine (MCV) in every district, delivered through the routine immunization program or through supplementary immunization activities (SIAs); 2) developing and sustaining a sensitive and timely measles case-based surveillance system that meets minimum recommended performance indicators; 3) developing and maintaining an accredited measles laboratory network; and 4) achieving timely identification, investigation, and response to measles outbreaks. In 2013, Nepal, one of the 11 SEAR member states, adopted a goal for national measles elimination by 2019. This report updates a previous report and summarizes progress toward measles elimination in Nepal during 2007-2014. During 2007-2014, estimated coverage with the first MCV dose (MCV1) increased from 81% to 88%. Approximately 3.9 and 9.7 million children were vaccinated in SIAs conducted in 2008 and 2014, respectively. Reported suspected measles incidence declined by 13% during 2007-2014, from 54 to 47 cases per 1 million population. However, in 2014, 81% of districts did not meet the measles case-based surveillance performance indicator target of ≥2 discarded non-measles cases per 100,000 population per year. To achieve and maintain measles elimination, additional measures are needed to strengthen routine immunization services to increase coverage with MCV1 and a recently introduced second dose of MCV (MCV2) to ≥95% in all districts, and to enhance sensitivity of measles case-based surveillance by adopting a more sensitive case definition, expanding case-based surveillance sites nationwide, and ensuring timely transport of specimens to the accredited national laboratory.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26937619     DOI: 10.15585/mmwr.mm6508a3

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  4 in total

1.  Who gets vaccinated in a measles-rubella campaign in Nepal?: results from a post-campaign coverage survey.

Authors:  M Carolina Danovaro-Holliday; Dale A Rhoda; Mona Lacoul; Mary L Prier; Jhalak Sharma Gautam; Tara Nath Pokhrel; Sameer Mani Dixit; Rajesh Man Rajbhandari; Anindya Sekhar Bose
Journal:  BMC Public Health       Date:  2022-02-03       Impact factor: 3.295

2.  Adapting Nepal's polio eradication programme.

Authors:  Krishna P Paudel; Lee M Hampton; Santosh Gurung; Rajendra Bohara; Indra K Rai; Sameer Anaokar; Rachel D Swift; Stephen Cochi
Journal:  Bull World Health Organ       Date:  2016-11-25       Impact factor: 9.408

3.  Measles and Rubella Seroprevalence in Mother-Infant Pairs in Rural Nepal and the United States: Pre- and Post-Elimination Populations.

Authors:  Alastair F Murray; Janet A Englund; James M Tielsch; Joanne Katz; Laxman Shrestha; Subarna K Khatry; Kristen Carlin; Steven C Leclerq; Mark C Steinhoff; Helen Y Chu
Journal:  Am J Trop Med Hyg       Date:  2018-11       Impact factor: 2.345

4.  Status of Measles Elimination in Eleven Countries with High Routine Immunisation Coverage in The WHO African Region.

Authors:  Balcha Masresha; Richard Luce; Messeret Shibeshi; Reggis Katsande; Amadou Fall; Joseph Okeibunor; Goitom Weldegebriel; Richard Mihigo
Journal:  J Immunol Sci       Date:  2018-07-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.